Lilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 16 · Tue 29 Sep 

The register

Every trial record behind this publication, one ray per row, and the newest reach furthest. Rays are placed by start date, or by the trial's first regulatory decision where the registry publishes no start date; one row with neither sits short by the origin.

NCT05347849Phase 1 · Pharmacokinetics in Healthy AdultsNCT05624268Phase 3 · Treatment Resistant DepressionNCT05660642Phase 2 · Treatment Resistant DepressionNCT05711940Phase 3 · Treatment Resistant DepressionNCT05804708Phase 2 · Postpartum Depression; Postnatal Depression2023-510047-37-00Phase 2 · Treatment-resistant depression (TRD)NCT05839509Phase 2 · Bipolar II DisorderNCT05800860Phase 2 · Treatment-resistant DepressionNCT05674929Phase 2 · Alcohol Use Disorder2024-513457-70-00Phase 2 · Treatment-Resistant Depression (TRD)NCT05870540Phase 2 · Treatment Resistant Depression2023-505268-12-00Phase 3 · Treatment-resistant depressionNCT06741228Phase 3 · Generalized Anxiety DisorderNCT06524830Phase 2 · Treatment Resistant DepressionNCT06809595Phase 3 · Generalized Anxiety DisorderNCT06941844Phase 3 · Major Depressive DisorderNCT06605105Phase 3 · Major Depressive Disorder2024-513572-17-00Phase 3 · Generalized Anxiety Disorder (GAD)NCT07286175Phase 2 · Bipolar DisorderNCT06793397Phase 3 · Major Depressive Disorder (MDD); Depression in Adults and 4 moreNCT07412756Phase 3 · Depressive Disorder, Major2025-522640-41-00Phase 2 · Uncontrolled moderate to severe asthma2025-522312-16-00Phase 3 · Alcohol Use Disorder2025-522313-38-00Phase 3 · Alcohol Use DisorderNCT07592689Phase 3 · Major Depressive Disorder2025-521488-11-00Phase 2 · Posttraumatic stress disorder2024-516805-22-00Phase 3 · Major Depressive DisorderNCT07210112Phase 2 · Depression - Major Depressive Disorder; Treatment-resistant Depression (TRD)NCT07169747Phase 2 · Anorexia NervosaNCT07775300Phase 3 · Depressive Disorder, Major2025-524939-39-02Phase 2 · Anorexia nervosa2025-524974-41-00Phase 2 · Irritable Bowel Syndrome - Constipation2025-523346-27-00Phase 2 · Treatment-Resistant Depression2025-522310-24-00Phase 3 · Depressive Disorder, Major2025-524973-17-00Phase 2 · Irritable Bowel Syndrome Diarrhea2024-515184-65-01Phase 2 · Post-traumatic stress disorderNCT07824973NA · Treatment Resistant Depression (TRD)NCT07792538Phase 2 · Posttraumatic Stress Disorder (PTSD)2024-515163-63-00Phase 2 · Anorexia Nervosa

39 records, read from primary registries. The table

Trials

One row per registry record, 39 in all. Every one read off a primary registry, with the date it was checked. The two registries are listed separately because their country columns do not mean the same thing.

EU Clinical Trials Information System 16

Member states whose regulator has a decision on the trial. CTIS publishes no primary completion date.

RecordAssetPhaseIndicationStatusMember states concernedVerified
2023-505268-12-00COMP360Therapeutic confirmatory (Phase III)Treatment-resistant depressionAuthorisedCzechia, Denmark, France, Germany, Ireland, Netherlands, Poland, Spain, Sweden2026-08-31
2023-510047-37-00GH001Therapeutic exploratory (Phase II)Treatment-resistant depression (TRD)EndedCzechia, Germany, Ireland, Poland, Spain2026-08-31
2024-513457-70-00BPL-003Therapeutic exploratory (Phase II)Treatment-Resistant Depression (TRD)EndedGermany, Poland, Spain2026-08-31
2024-513572-17-00DT120 (registry title MM120)Therapeutic confirmatory (Phase III)Generalized Anxiety Disorder (GAD)AuthorisedCzechia, France, Germany, Poland2026-08-31
2024-515163-63-00psilocybin (investigator-led)Therapeutic exploratory (Phase II)Anorexia NervosaAuthorisedSweden2026-08-31
2024-516805-22-00CYB003Therapeutic confirmatory (Phase III)Major Depressive DisorderAuthorisedCzechia, Germany, Greece, Ireland, Poland2026-08-31
2025-522310-24-00brenipatide (LY3537031)Therapeutic confirmatory (Phase III)Depressive Disorder, MajorAuthorisedGermany, Greece, Poland, Spain2026-08-31
2025-522312-16-00brenipatide (LY3537031)Therapeutic confirmatory (Phase III)Alcohol Use DisorderAuthorisedBelgium, Germany2026-09-15
2025-522313-38-00brenipatide (LY3537031)Therapeutic confirmatory (Phase III)Alcohol Use DisorderAuthorisedBelgium, Germany2026-08-31
2025-524973-17-00brenipatide (LY3537031)Therapeutic exploratory (Phase II)Irritable Bowel Syndrome DiarrheaAuthorisedBelgium, Germany, Poland, Spain2026-08-31
2025-524974-41-00brenipatide (LY3537031)Therapeutic exploratory (Phase II)Irritable Bowel Syndrome - ConstipationAuthorisedBelgium, Spain2026-08-31
2025-521488-11-00psilocybin (investigator-led; PEX010 capsules, 25 mg and 5 mg)Therapeutic exploratory (Phase II)Posttraumatic stress disorderAuthorisedNetherlands2026-09-08
2025-524939-39-02psilocybin (investigator-led; PEX010)Therapeutic exploratory (Phase II)Anorexia nervosaAuthorisedDenmark2026-09-08
2025-523346-27-00psilocybin with trazodone (investigator-led; PEX010 25 mg and Trittico)Therapeutic exploratory (Phase II)Treatment-Resistant DepressionAuthorisedItaly2026-09-08
2024-515184-65-01MDMA hydrochloride (investigator-led)Therapeutic exploratory (Phase II)Post-traumatic stress disorderAuthorisedNetherlands2026-09-08
2025-522640-41-00brenipatide (LY3537031)Therapeutic exploratory (Phase II)Uncontrolled moderate to severe asthmaAuthorisedGermany, France, Netherlands, Poland2026-09-15

ClinicalTrials.gov 23

The sponsor's registered location list, which states intent rather than approval.

RecordAssetPhaseIndicationStatusRegistered countriesVerified
NCT05347849BPL-003PHASE1Pharmacokinetics in Healthy AdultsCOMPLETEDUnited Kingdom2026-08-31
NCT05624268COMP360PHASE3Treatment Resistant DepressionCOMPLETEDUnited States2026-08-31
NCT05660642BPL-003PHASE2Treatment Resistant DepressionRECRUITINGUnited Kingdom2026-08-31
NCT05674929BPL-003PHASE2Alcohol Use DisorderCOMPLETEDUnited Kingdom2026-08-31
NCT05711940COMP360PHASE3Treatment Resistant DepressionACTIVE_NOT_RECRUITINGCanada, Czechia, Denmark, France, Germany, Ireland, Netherlands, Poland, Spain, Sweden, United Kingdom, United States2026-08-31
NCT05800860GH001PHASE2Treatment-resistant DepressionCOMPLETEDCzechia, Germany, Ireland, Netherlands, Poland, Spain2026-08-31
NCT05804708GH001PHASE2Postpartum Depression;Postnatal DepressionTERMINATEDNetherlands, United Kingdom2026-08-31
NCT05839509GH001PHASE2Bipolar II DisorderTERMINATEDGermany, Netherlands, United Kingdom2026-08-31
NCT05870540BPL-003PHASE2Treatment Resistant DepressionCOMPLETEDAustralia, Germany, Poland, Spain, United Kingdom, United States2026-09-15
NCT06524830VLS-01PHASE2Treatment Resistant DepressionRECRUITINGAustralia, Canada, United Kingdom, United States2026-08-31
NCT06605105CYB003PHASE3Major Depressive DisorderENROLLING_BY_INVITATIONAustralia, United States2026-08-31
NCT06741228DT120 (registry title MM120)PHASE3Generalized Anxiety DisorderACTIVE_NOT_RECRUITINGUnited States2026-09-15
NCT06793397CYB003PHASE3Major Depressive Disorder (MDD);Depression in Adults;Depression - Major Depressive Disorder;Depression Disorders;Depression Disorder;DepressionRECRUITINGAustralia, Czechia, Germany, Greece, Ireland, Poland, United Kingdom, United States2026-08-31
NCT06809595DT120 (registry title MM120)PHASE3Generalized Anxiety DisorderACTIVE_NOT_RECRUITINGCzechia, France, Germany, Poland, United Kingdom, United States2026-09-08
NCT06941844DT120 (registry title MM120)PHASE3Major Depressive DisorderACTIVE_NOT_RECRUITINGUnited States2026-08-31
NCT07169747psilocybin (investigator-led)PHASE2Anorexia NervosaRECRUITINGSweden2026-08-31
NCT07286175brenipatide (LY3537031)PHASE2Bipolar DisorderRECRUITINGArgentina, Brazil, China, India, Japan, Mexico, Puerto Rico, United States2026-08-31
NCT07412756brenipatide (LY3537031)PHASE3Depressive Disorder, MajorRECRUITINGAustralia, Brazil, Canada, China, Germany, Greece, Japan, Mexico, Poland, Puerto Rico, South Korea, Spain, Taiwan, United Kingdom, United States2026-08-31
NCT07592689DT120 (registry title MM120)PHASE3Major Depressive DisorderRECRUITINGUnited States2026-08-31
NCT07775300brenipatide (LY3537031)PHASE3Depressive Disorder, MajorNOT_YET_RECRUITINGAustralia, Brazil, Canada, China, Germany, Greece, Japan, Mexico, Poland, Puerto Rico, South Korea, Spain, Taiwan, United Kingdom, United States2026-08-31
NCT07792538psilocybin (investigator-led; PEX010 capsules, 25 mg and 5 mg)PHASE2Posttraumatic Stress Disorder (PTSD)NOT_YET_RECRUITINGNetherlands2026-09-08
NCT07824973noneNATreatment Resistant Depression (TRD)NOT_YET_RECRUITINGSweden2026-09-22
NCT07210112nonePHASE2Depression - Major Depressive Disorder; Treatment-resistant Depression (TRD)RECRUITINGFrance2026-09-22